News
5h
Adweek on MSNEli Lilly's Big Task: Become a Loved and Trusted Pharma BrandA new film from Eli Lilly sounds like a recruitment ad, but it doubles as a brand manifesto to showcase the pharmaceutical ...
Aide to RFK Jr. says White House is pushing for global price parity on GLP-1 drugs for weight loss. Read more here.
Eli Lilly and Company (NYSE:LLY) is a leading medicine company which discovers, develops, manufactures, and markets products ...
19h
Zacks Investment Research on MSNETFs to Capitalize on the Novo Nordisk-Septerna DealNovo Nordisk NVO announced a significant partnership with Septerna SEPN, a U.S.-based biotech company, valued at up to $2.2 billion, to tap the growing obesity treatment market. Following the ...
Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...
Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...
As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results